Drug Discovery Re-Invented; Emerging Role of Biotechs, Academics and Non-Profits (DDRI)

Venue: Hilton Scottsdale Resort & Villas

Location: Scottsdale, Arizona, United States

Event Date/Time: Oct 16, 2013 / 10:00 am - (MST) End Date/Time: Oct 19, 2013 / 1:30 pm - (MST)
Registration Date: Aug 21, 2013 Time: 12:00:00 - (MST)
Early Registration Date: May 01, 2013 Time: 12:00:00 - (MST)
Abstract Submission Date: May 20, 2013 Time: 12:00:00 - (MST)
Report as Spam

Description

Registration Deadline: 21st August 2013

The full programme is now available, please see conference website for details. The conference will center on new approaches to drug discovery in an industry where the landscape is changing rapidly. With large pharma reducing investment in internal early stage research, drug pipelines will increasingly be filled by alternative sources. These players include: government, academic labs, non-profits, biotech companies, and pharmaceutical “open innovation” models. The conference will also provide examples of successful strategies for advancing new drug candidates in this era of distributed discovery.

Key Sessions include:

  1. Discovery Re-Invented
  2. Novel Pharma Approaches
  3. Collaborative Drug Discovery
  4. Natural Products
  5. Structure, Modelling and Informatics
  6. Biologics and Non-traditional Therapeutics
  7. Discovery Technologies
  8. Exclusive Exhibit (please contact us for booth pricing, limited availability)

This conference is designed to attract the following attendees: medicinal, computational, and synthetic organic chemists; structural and screening biologists; research management and entrepreneurs; industrial and academic scientists.

Confirmed Speakers

Prof. William Jorgensen (Plenary) ,Yale University

Prof. Jef De Brabander, UT Southwestern Medical

Dr. Bart DeCorte, Janssen Research & Development

Prof. James Barrow, Johns Hopkins School of Medicine

Dr. Ken Duncan (Plenary), Bill & Melinda Gates Foundation

Dr. Guy Breitenbucher, Dart Neuroscience

Dr. Barry Bunin, Collaborative Drug Discovery

Dr. Paul Labute, Chemical Computing Group

Dr. Leah Frye, Schrödinger

Prof. Sean Brady, The Rockefeller University

Dr. Steven Young (Plenary) BeiGene

Dr. Craig Thomas, NIH Chemical Genomics Center

Dr. Michael Trzoss, Trius Therapeutics

Dr. Joseph Vacca, WuXi AppTec

Dr. Michael Goetz, Natural Products Discovery Institute

Prof. George Georgiou (Plenary),  The University of Texas at Austin

Dr. Benjamin Blass, Temple University School of Pharmacy

Prof. Kenneth Merz, University of Florida

Dr. Michael Foley (Plenary), Broad Institute

Dr. David Gorenstein, University of Texas HSC Houston

Dr. Zhengying Pan, Peking University, Shenzhen Graduate School

Dr. Andreas G. Bader, Mirna Therapeutics

Dr. Todd Chappell, NIH and BioHealth Innovation

Dr. Trevor Hallam, Sutro Biopharma

Dr. Patrick Lam, Lam Drug Discovery Consulting

Dr. Sandhya Kortagere, Drexel University College of Medicine

Dr. Mark McDonnell, Fox Chase Chemical Diversity Center

Dr. Serge L Boulet, Eli Lilly

Dr. Gabor Butora, Merck

Dr. Janet L. Ralbovsky, University of Tennessee Research Foundation

Dr Paul Leeson, GlaxoSmithKline

Dr Matthew Segall, Optibrium Ltd.

Dr. Guy Carter, Biosortia Pharmaceuticals

Dr Chris Williams, Chemical Computing Group

Dr. Phil Cox, Noramco

Dr. David Lowe, Æglea BioTherapeutics

Dr. Kristopher Josephson, Ra Pharmaceuticals

Dr. Erin Duffy, Rib-X

Dr. Joel Dudley, Mount Sinai School of Medicine

 

Venue

6333 North Scottsdale Road,
Scottsdale
Arizona
United States
MORE INFO ON THIS VENUE

Additional Information

Registration Deadline: 21st August 2013

The full programme is now available, please see conference website for details.

Exclusive Exhibit (please contact us for booth pricing, limited availability)